These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 23231513

  • 1. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S, Stein K, Kotulska K.
    Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
    Lancet; 2013 Jan 12; 381(9861):125-32. PubMed ID: 23158522
    [Abstract] [Full Text] [Related]

  • 3. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.
    Lancet Oncol; 2014 Dec 12; 15(13):1513-1520. PubMed ID: 25456370
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.
    Komotar RJ, Starke RM, Connolly ES, Sisti MB.
    Neurosurgery; 2011 Apr 12; 68(4):N24-5. PubMed ID: 21792104
    [No Abstract] [Full Text] [Related]

  • 7. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J, Dachowska I, Kotulska K, Baranska D, Fendler W, Jozwiak S, Mlynarski W.
    Pediatr Blood Cancer; 2015 Apr 12; 62(4):616-21. PubMed ID: 25557360
    [Abstract] [Full Text] [Related]

  • 8. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.
    Yalon M, Ben-Sira L, Constantini S, Toren A.
    Childs Nerv Syst; 2011 Jan 12; 27(1):179-81. PubMed ID: 20703486
    [Abstract] [Full Text] [Related]

  • 9. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN.
    N Engl J Med; 2010 Nov 04; 363(19):1801-11. PubMed ID: 21047224
    [Abstract] [Full Text] [Related]

  • 10. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A, De Waele L, Bartalini G, Jozwiak S, Laforgia N, Verhelst H, Petrak B, Pedespan JM, Witt O, Castellana R, Crippa S, Gislimberti G, Gyorsok Z.
    BMC Neurol; 2016 Aug 08; 16():126. PubMed ID: 27502586
    [Abstract] [Full Text] [Related]

  • 11. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.
    Rev Neurol; 2014 Dec 01; 59(11):497-502. PubMed ID: 25418144
    [Abstract] [Full Text] [Related]

  • 12. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.
    Expert Opin Pharmacother; 2011 Oct 01; 12(14):2265-9. PubMed ID: 21806479
    [Abstract] [Full Text] [Related]

  • 13. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
    Jia J, Xiong L, Chen S.
    N Engl J Med; 2011 Feb 10; 364(6):577. PubMed ID: 21306252
    [No Abstract] [Full Text] [Related]

  • 14. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Curran MP.
    Paediatr Drugs; 2012 Feb 01; 14(1):51-60. PubMed ID: 22136276
    [Abstract] [Full Text] [Related]

  • 15. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN.
    Expert Rev Anticancer Ther; 2011 Aug 01; 11(8):1181-92. PubMed ID: 21916571
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Niolat J, Jóźwiak S.
    PLoS One; 2016 Aug 01; 11(6):e0158476. PubMed ID: 27351628
    [Abstract] [Full Text] [Related]

  • 17. Rapamycin and rapalogs for tuberous sclerosis complex.
    Sasongko TH, Ismail NF, Zabidi-Hussin Z.
    Cochrane Database Syst Rev; 2016 Jul 13; 7(7):CD011272. PubMed ID: 27409709
    [Abstract] [Full Text] [Related]

  • 18. Everolimus.
    Hasskarl J.
    Recent Results Cancer Res; 2014 Jul 13; 201():373-92. PubMed ID: 24756805
    [Abstract] [Full Text] [Related]

  • 19. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ, Franz DN, Frost MD, Belousova E, Bebin EM, Sparagana S, Berkowitz N, Ridolfi A, Kingswood JC.
    Pediatr Nephrol; 2018 Jan 13; 33(1):101-109. PubMed ID: 28993887
    [Abstract] [Full Text] [Related]

  • 20. Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report.
    Wiemer-Kruel A, Woerle H, Strobl K, Bast T.
    Neuropediatrics; 2014 Apr 13; 45(2):129-31. PubMed ID: 24293099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.